Business Wire

2023 World Baseball Classic Begins, Taiwan Excellence Supports

8.3.2023 11:10:00 EET | Business Wire | Press release

Share

The World Baseball Classic (WBC) is returning to Taiwan, after a ten-year hiatus, for the qualifying rounds. The tournament will feature teams from Taiwan, the Netherlands, Cuba, Italy, and Panama, who will showcase their skills starting on March 8th. As the host country for the A-group preliminaries, Taiwan extends a warm welcome to the players through enthusiastic fans, fascinating cuisine, and the opportunity to experience the latest Taiwan Excellence awarded technology and lifestyle products.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230311005004/en/

The WBC was postponed for two years due to the impact of COVID-19. With hygiene and safety being top priorities, Major League Baseball (MLB) has adopted stringent standards for the event. The Taiwanese organizers have prepared the world's first indoor wireless rapid antibacterial machine, the AQUECARE T1 Plus sanitizer. This innovative solution has received the Taiwan Excellence Award and will play a vital role in maintaining environmental hygiene throughout the tournament.

Because long-haul flights can cause fatigue among players, posing them a significant challenge, the organizers have provided the world's first AURAI intelligent eye massager in order to facilitate more rapid recovery. This device helps to alleviate eye fatigue, improves sleep quality, and will recharge energy levels for the players. They will also be able to use AROMASE all-in-one purifying gel which contains three different types of herbal extracts. This gel is effective in purifying the body and mind after each training session and competition. Furthermore, we prioritize environmental sustainability, and have prepared O’right toothpaste, a revolutionary toothpaste made from sustainable tree powder as a grinding agent. This toothpaste is certified by USDA Biobased.

Taiwan is well-known as a technology island, and its consumer electronics and ICT products have gained recognition from consumers worldwide. So, the organizers are providing the players with another Taiwan Excellence awarded product, the PX 4K HDR Wireless Presentation Receiver. This product supports 4K HDR wireless transmission and provides a convenient 4K wireless projection function from mobile phones and laptops to televisions, enabling players to relax and enjoy different forms of entertainment when away from the intensity of competition.

As a souvenir for players from around the world, the Qubii auto-backup device has been chosen. This is a hand-sized device that automatically backs up photos, videos, contacts, and other content while your phone is charging. This device allows players to easily back up precious game data and memories when they run out of phone storage.

Taiwan is making every effort to provide a comfortable and safe environment with the very best professional equipment, in the hopes that the teams will enjoy their stay in Taiwan and maximize their performance in the WBC. Taiwan Excellence, a globally recognized symbol of product quality and innovative design, plays an important role in this commitment. Taiwan Excellence will continue to discover and introduce more high-quality Taiwanese products, featuring innovative breakthroughs to the world, enriching the lives of people everywhere.

For more information, please visit our website https://www.taiwanexcellence.org/en

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Brain Lee, TAITRA
brianlee@taitra.org.tw

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye